Bulk Inquiry
GDC 0980
- RG 7422 - GNE 390 - Apitolisib
- Soluble in DMSO
- MF: C23H30N8O3S
- MW: 498.6
Description
More Information
| Parent CAS No. | 1032754-93-0 |
|---|---|
| Chemical Name | (S)-1-(4-((2-(2-aminopyrimidin-5-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-6-yl)methyl)piperazin-1-yl)-2-hydroxypropan-1-one |
| MFCD | N.A. |
| Short Description | PI3K/mTOR inhibitor |
References
- JJ Wallin et al. GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway. Mol. Cancer Ther. 2011, 10(12), 2426-2436.
- AJ Wagner et al. A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors. J. Clin. Oncol. 2011, 29 (suppl; abstr 3020).
- DP Sutherlin et al. Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer. J. Med. Chem. 2011, 54(21), 7579-87.
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1281 | BEZ 235 |
From $55.00 |
| 1282 | BAG 956 |
From $104.50 |
| 1334 | PIK 75 hydrochloride |
From $77.00 |
| 1362 | PIK 90 |
From $93.50 |
| 1366 | LY 294002 |
From $77.00 |
| 1367 | KU-55933 |
From $121.00 |
| 1377 | GDC 0941 bismesylate |
From $88.00 |
| 1380 | PI 103 hydrochloride |
From $66.00 |
| 1417 | TGX 221 |
From $77.00 |
| 1424 | AS 252424 |
From $93.50 |
| 1436 | AS 252424 bispotassium salt |
From $104.50 |
| 1463 | NU 7441 |
From $44.00 |
| 1472 | KU-0063794 |
From $66.00 |
| 1495 | CP 466722 |
From $77.00 |
| 1520 | NVP-BBD130 |
From $137.50 |
| 1561 | AZD8055 |
From $88.00 |
| 1596 | GSK 2126458 |
From $55.00 |
| 1699 | Temsirolimus |
From $104.50 |
| 1706 | XL PI3K/mTOR inhibitor |
From $132.00 |
| 1718 | Palomid 529 |
From $99.00 |
| 1719 | D 106669 |
From $93.50 |
| 1797 | NVP-BKM120 |
From $99.00 |
| 1807 | PKI 587 |
From $99.00 |
| 1831 | A 66 |
From $104.50 |
